Clinical Trial Update: Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis [Phase 2]

View source ↗

Summary

A Phase 2 study completed to evaluate cannabidiol as a potential antipsychotic in acute schizophrenia, assessing its efficacy in reducing psychotic symptoms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: University of Cologne | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED